Search results
Showing 76 to 90 of 100 results for methotrexate
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
a conventional disease-modifying antirheumatic drug (DMARD), such as methotrexate. For axial SpA we recommend offering a non-steroidal...
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: TBC
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued [GID-TA10527]
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Discontinued [GID-TAG402]
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Find out more about NICE technology appraisals advisory committee D members
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
Birch bark extract for treating epidermolysis bullosa (HST28)
Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.